ACR basic and clinical research conference: rheumatologic complications of emerging viral infections / sars-COV-2
Ended Cooperative Agreement Awarded Last action
- Award ID
- U13AR079881
- Recipient
-
American College Of Rheumatology, Inc. UEI JX1ASDAR5VN7
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $157,220
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Funding
-
- $107,220.22 Federal
- $50,000.00 Non-federal
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- Place of performance
- Georgia, USA
Award details come from USAspending.gov.
Description
- Abstract
- Abstract the american college of rheumatology (ACR) has been a leader in the effort to facilitate the bidirectional exchange of cutting-edge scientific information between scientists and investigators in rheumatic diseases through its annual basic and clinical research conferences. Historically, these scientific symposia have occurred immediately prior to the ACR annual meeting at the site of the meeting. This past year, based on the pandemic restrictions, these symposia were hosted virtually as a post-event to the annual meeting. The ACR annual meeting, ACR convergence, attracts more than 15,000 attendees each year and is the principal mechanism for providing a forum for the exchange of ideas about research, education, patient care, practice management and advocacy issues. Because the basic and clinical research conferences are pre- meeting events for ACR convergence, ACR has been able to attract renown scientists and investigators who may otherwise not have attended. For 2021, the basic and clinical research conferences will be held jointly to attract scientists and investigators from both the basic, clinical and translational research communities. The title of the conference will be rheumatologic complications of emerging viral infections / sars-COV-2. This combined approach will focus on emerging viral infections, especially as they relate to sars-COV-2. This deadly global pandemic has provided an enormous influx of data relevant to rheumatologists. Not only is the rheumatologist confronted with managing her/his own patients with rheumatic diseases on various anti-rheumatic therapies, but viruses like sars-COV-2 are responsible for triggering rheumatologic complications among a substantial number of infected individuals. Rheumatologists have an important role to play in diagnosing and treating these complications. Moreover, rheumatologists have expertise in many of the biologic therapeutics being employed to treat severe sars-COV-2 infections. Ever expanding knowledge from viral pandemics is important to share with rheumatologists who are integral to the care of infected individuals worldwide. Clinical research sessions will focus on topics such as the impact of covid-19 vaccines for immunocompromised hosts, cytokine storm syndrome, and dermatologic manifestations of covid-19. Basic research sessions will explore topics such as auto-antibodies to type 1 interferon and other cytokines, anti- phospholipid antibodies and their role in comorbidities, and neutrophil dysregulation and nets in covid-19. The conference organizers include DR. Randy cron, professor of pediatrics and medicine at the university of alabama at birmingham (UAB) and the arthritis foundation, alabama chapter endowed chair in pediatric rheumatology. DR. Cron is the director of the division of pediatric rheumatology and the pediatric rheumatology fellowship program at children's of alabama; DR. Mariana kaplan, niams chief of the systemic autoimmunity branch. She is also deputy scientific director at niams; and ACR committee on research (DR. Kristine kuhn, chair). The ACR committee on research focuses on research and research training in rheumatology and encourages clinical and health services research on the organization of medical and health care as they may affect patients with rheumatic diseases. DR. Kuhn, chair, is associate professor, medicine-rheumatology at the university of colorado anschutz medical campus.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $9,747 | $0 | |
| Amendment | $780 | $0 | |
| Amendment | $9,747 | $0 | |
| Amendment | $780 | $0 | |
| Amendment | -$780 | $0 | |
| Amendment | -$9,747 | $0 | |
| Amendment | -$780 | $0 | |
| Amendment | -$780 | $0 | |
| Amendment | -$9,747 | $0 | |
| Amendment | $4,000 | $0 | |
| Amendment | $50,000 | $0 | |
| Amendment | $4,000 | $0 | |
| Original award | $50,000 | $50,000 |
Show all 13
Quick answers
Who received award U13AR079881?
U13AR079881 was awarded to American College Of Rheumatology, Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on August 10, 2021.
How much is award U13AR079881 worth?
$157,220 has been obligated on U13AR079881: $107,220 in federal funding and $50,000 in non-federal funding.
Which agency awarded U13AR079881?
National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) awarded U13AR079881, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award